性结肠炎增加了心阻塞的风险:来自孟德尔随机分析的证据
Wanqiong Shu1, Guanghong Huang2
1Affiliated Guangdong Hospital of Integrated Traditional Chinese and Western Medicine of Guangzhou University of Chinese Medicine, No.16, Guicheng South Fifth Road, Nanhai District, Foshan, 528200, China.
Scientific reports
|April 8, 2025
概括
炎症性肠道疾病 (IBD),特别是性结肠炎 (UC),可能会增加发展心房静脉阻塞 (AVB) 的风险. 这项研究使用了门德尔的随机化来探索IBD和心律失常之间的因果关系.
科学领域:
- 心血管医学 心血管医学
- 胃肠病学 胃肠病学
- 遗传学 是一个遗传学.
背景情况:
- 越来越多的证据将炎症性肠病 (IBD) 与心血管疾病联系起来.
- IBD和心律失常之间的具体关系在很大程度上仍未确定.
研究的目的:
- 使用孟德尔随机化研究炎症性肠病 (IBD) 和特定心律失常现象类型之间的潜在因果关系.
- 评估IBD亚型 (性结肠炎和克罗恩病) 与心房阻塞 (AVB) 和心性心力衰竭 (PTA) 之间的关联.
主要方法:
- 两个样本的孟德尔随机化分析使用与IBD (包括UC和CD) 相关的单核酸多态 (SNPs) 作为仪器变量.
- 对心室膜阻塞 (AVB) 和心跳动 (PTA) 的结果数据使用逆方差加权和其他MR方法进行了分析.
- 为了确保结果的有效性,进行了敏感性分析,包括异质性,性和留出一个分析,使用了MR-Egger回归和加权中位数方法.
主要成果:
- 发现性结肠炎 (UC) 与心阻塞 (AVB) 的风险增加之间存在显著的关联 (OR 1.178,P=0.000828).
- MR-Egger回归和加权中位数方法证实了这一关联.
- 使用独立数据集的验证分析证实了这些发现 (OR 1.048,P=0.022947).
结论:
- 性结肠炎 (UC) 可能与发展心房静脉阻塞 (AVB) 的风险增加有关.
- 这些发现表明,炎症性肠病 (IBD) 在增加心律不整的风险方面可能发挥作用.
- 需要进一步的研究来阐明这种关联背后的机制.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
98
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
98
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Disturbances in Heart Rhythm
729
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
729
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
407
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
407
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
846
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
846
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
665
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
665


